NCT03894618View on ClinicalTrials.gov

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid Tumors
Interventions
DRUG

SL-279252

The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).

Trial Locations (5)

3000

Leuven Cancer Institute, Leuven

37203

The Sarah Cannon Research Institute, Nashville

77030

The University of Texas MD Anderson Cancer Center, Houston

M5G 1Z5

Princess Margaret Cancer Center, Toronto

08035

Vall d'Hebron Institut D' Oncologia, Barcelona

All Listed Sponsors
lead

Shattuck Labs, Inc.

INDUSTRY

NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Biotech Hunter | Biotech Hunter